

In the Claims:

Claims 1-24 (Cancelled)

25. (Currently Amended): An isolated, recombinant polypeptide comprising a member selected from the group consisting of

- (a) ~~the an amino acid sequence SEQ ID NO:2 comprising the sequence set forth in SEQ ID NOs:2 or 4;~~
- (b) ~~an immunogenic polypeptide comprising a fragment sequence of at least 15 contiguous of SEQ ID NO:2 amino acids that corresponds to an aligned contiguous segment of one of SEQ ID NOs:2 or 4,~~

wherein the immunogenic fragment ~~isolated polypeptide~~, when administered to a subject in a suitable composition which can include an adjuvant, or a suitable carrier coupled to the polypeptide, induces an antibody or T-cell mediated immune response that recognizes ~~to a the~~ polypeptide SEQ ID NO:2 ~~having the sequence of one of SEQ ID NOs:2 or 4.~~

26. (Cancelled)

27. (Currently Amended): The isolated, recombinant polypeptide of claim 25, wherein the polypeptide is according to (a).

28. (Cancelled)

29. (Currently Amended): The isolated, recombinant polypeptide of claim 25, wherein the polypeptide is according to (b).

30. (Cancelled)

31. (Currently Amended): The isolated, recombinant polypeptide of claim 25, wherein the immunogenic fragment of (b) comprises at least 20 contiguous amino acids; wherein the immunogenic fragment, when administered to a subject in a suitable composition which can include an adjuvant, or a suitable carrier coupled to the polypeptide, induces an antibody or T-cell mediated immune response that recognizes the polypeptide SEQ ID NO:2.

32. (Currently Amended): The isolated, recombinant polypeptide of claim 25 consisting of ; ~~wherein the amino acid sequence of (a) is according to~~ SEQ ID NO:2.

Claims 33-42 (Cancelled)

43. (Currently Amended): An immunogenic composition comprising the isolated, recombinant polypeptide of Claim 25 and a pharmaceutically acceptable carrier.

44. (Previously Presented): The immunogenic composition of Claim 43, wherein the immunogenic composition comprises at least one other *Neisseria meningitidis* antigen in addition to an antigen provided by the polypeptide.

45. (Cancelled)

46. (Currently Amended): A method for inducing an immune response in a mammal comprising administration of the isolated, recombinant polypeptide of Claim 25.

Claims 47-49 (Cancelled)

50. (New): A fusion protein comprising the isolated, recombinant polypeptide of claim 27.

51. (New): An immunogenic composition comprising the isolated, recombinant polypeptide of claim 27.
52. (New): A fusion protein comprising the isolated, recombinant polypeptide of claim 29.
53. (New): An immunogenic composition comprising the isolated, recombinant polypeptide of claim 29.
54. (New): An immunogenic composition consisting of the amino acid sequence SEQ ID NO:2.